HQY stock forecast, quote, news & analysis
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions... Show more
HealthEquity (HQY) Stock Analysis: Margin Expansion and HSA Growth Sustain Upward Momentum
Key Takeaways
- HealthEquity shares climbed approximately 7% over the last 30 days, extending a broader multi-month uptrend driven by strong fiscal first-quarter results and raised guidance.
- The company beat Wall Street estimates in late May 2026, reporting adjusted EPS of $1.24 versus the $1.11 consensus, while revenue rose 7.2% year-over-year to $354.6 million.
- Analyst sentiment remains broadly positive, with a consensus Moderate Buy/Strong Buy rating and price targets ranging from $105 to $135, supported by expanding gross and operating margins.
- Total HSA assets reached $37.1 billion as of April 30, 2026, up 19% year-over-year, underscoring the company's dominant position in the consumer-directed benefits market.
- Institutional ownership stands at 99.55%, though some insider selling under pre-arranged 10b5-1 plans and mixed institutional rebalancing were noted in recent filings.
Current Market Snapshot
HealthEquity (HQY) closed at $94.64 on July 24, 2026, reflecting a gain of roughly 7% over the preceding 30 calendar days. The stock has traded between a 52-week low of $72.76 and a high of $105.96, with a market capitalization of approximately $7.91 billion. The company carries a price-to-earnings ratio near 35.5 and a notably low beta of 0.21, indicating limited correlation with broader equity market swings. Trading volume has been moderate, with periodic spikes around earnings-related events and institutional rebalancing windows. The stock's 50-day and 200-day simple moving averages — around $90 and $85, respectively — point to a sustained uptrend that has remained largely intact since April 2026, supported by fundamental improvements and constructive analyst revisions.
HealthEquity (HQY) Business Overview and Competitive Position
HealthEquity, Inc., founded in 2002 and headquartered in Draper, Utah, is the largest independent administrator of health savings accounts (HSAs) and complementary consumer-directed benefits (CDBs) in the United States. The company manages over 17.8 million total accounts, including 10.6 million HSAs and 7.2 million CDBs such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration, and commuter benefits. HealthEquity generates revenue through three primary streams: service fees paid by employers and health plans, custodial fees earned on HSA cash balances, and interchange revenue from payment card transactions. Its open-architecture platform integrates with health plans, payroll providers, and financial institutions, offering members digital tools for account management, investment advisory services, and a growing healthcare marketplace. With $37.1 billion in total HSA assets under administration and a nationwide footprint, HealthEquity benefits from structural tailwinds including rising adoption of high-deductible health plans, growing healthcare costs, and increasing demand for tax-advantaged savings vehicles.
Recent Developments Driving HQY
HealthEquity's most significant catalyst in the last 30 days was the sustained positive reaction to its fiscal 2027 first-quarter earnings report, released on May 28, 2026. The company delivered adjusted earnings per share of $1.24, surpassing the Zacks Consensus Estimate by 11.7% and representing 28% growth year-over-year. Revenue came in at $354.6 million, edging past the $352 million consensus. Management raised its full-year fiscal 2027 guidance: revenue is now projected at $1.41 billion to $1.42 billion, with non-GAAP EPS of $4.66 to $4.73, up from the prior range of $4.56 to $4.65. Gross margin expanded 450 basis points to 72.3%, and operating margin improved 390 basis points to 29%, reflecting meaningful operating leverage.
On the analyst front, several firms raised price targets following the earnings release. RBC Capital lifted its target from $100 to $108 with an Outperform rating, BTIG raised its target from $110 to $115 with a Buy rating, and J.P. Morgan reiterated a Buy with a $123 target. Barclays and Bank of America also maintained constructive outlooks. Wall Street Zen, however, downgraded HQY from Buy to Hold in early July, citing valuation considerations. Overall, 11 analysts rate the stock a Buy, one rates it Hold, and one rates it Sell, with consensus price targets clustered around $110 to $118.
Institutional activity was mixed. Swedbank AB increased its stake by 61.5% in the first quarter, and Principal Financial Group added 26,632 shares. Conversely, WCM Investment Management and Bank of New York Mellon trimmed their positions. Insider selling — including transactions by Director Gayle Furgurson Wellborn and EVP Michael Henry Fiore — was conducted under pre-established Rule 10b5-1 trading plans and does not necessarily signal a negative outlook. The company's digital engagement metrics also drew attention: monthly active mobile usage surged 90% year-over-year, and management highlighted early marketplace traction in metabolic health, diagnostics, and men's health programs.
Trending AI Robots
Investors seeking data-driven, automated trading strategies may find value in Tickeron's Trending AI Robots page. Tickeron offers a broad ecosystem of hundreds of AI-powered trading bots that actively trade thousands of tickers across equity markets. The Trending AI Robots section curates a focused selection of top-performing and high-relevance bots, helping users quickly identify strategies that align with current market conditions. Each bot operates with distinct parameters — spanning different timeframes, risk profiles, and trading methodologies — allowing traders to evaluate performance metrics and choose approaches suited to their objectives. Whether targeting short-term momentum or longer-duration trend-following, the curated list provides a practical entry point into AI-assisted trading.
2026 Outlook and What Investors Should Watch
Looking ahead, HealthEquity's trajectory will likely be shaped by several key factors. First, the company's ability to sustain HSA account and asset growth remains central — management noted the addition of approximately 172,000 new HSAs in the fiscal first quarter, outpacing industry growth rates. Second, custodial yield dynamics tied to interest rate movements will remain important; HealthEquity has partially hedged this exposure with a cumulative $2.35 billion in 5-year Treasury bond hedges at 3.92%, but variable-rate contracts introduce some sensitivity. Third, the expansion of the healthcare marketplace — including metabolic health, diagnostics, and GLP-related programs — represents a high-margin growth opportunity, though adoption patterns are still developing. Fourth, competitive pressure from larger players such as UnitedHealth Group and Webster Financial warrants monitoring, particularly in employer-channel distribution. Finally, cybersecurity and regulatory developments remain ongoing risk factors, especially given the company's custody of sensitive health and financial data. With a forward P/E around 19.4 and expected EPS growth of roughly 18% in fiscal 2027, the stock's valuation will depend on execution against these catalysts and the broader interest rate environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HQY's Stochastic Oscillator slumps into oversold zone
The Stochastic Oscillator for HQY moved into oversold territory on July 24, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 24, 2026. You may want to consider a long position or call options on HQY as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
HQY moved above its 50-day moving average on June 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for HQY moved above the 200-day moving average on July 17, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HQY advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 282 cases where HQY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for HQY moved out of overbought territory on July 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for HQY turned negative on July 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HQY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HQY broke above its upper Bollinger Band on July 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HQY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.864) is normal, around the industry mean (7.295). P/E Ratio (35.444) is within average values for comparable stocks, (51.101). Projected Growth (PEG Ratio) (1.355) is also within normal values, averaging (1.487). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (6.131) is also within normal values, averaging (5.746).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HQY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of solutions for managing health care accounts
Industry ServicestotheHealthIndustry